Synairgen plc Holding(s) in Company (5177A)

TIDMSNG

RNS Number : 5177A

Synairgen plc

27 March 2017

Synairgen plc

('Synairgen' or the 'Company')

Holding in Company

Southampton, UK,: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that it received notice on 24 March 2017 that Leonard Licht, a private investor, now holds 3,700,000 ordinary shares of 1 pence each in the capital of the Company through Boal & Co (as Trustees of the Trinity Pension Scheme (ref L.S. Licht)).

This represents 4.05% of the total voting rights of the Company.

For further enquiries, please contact:

Synairgen plc

Richard Marsden, Chief Executive Officer

John Ward, Finance Director

Tel: + 44 (0) 23 8051 2800

finnCap

Geoff Nash, James Thompson (Corporate Finance)

Stephen Norcross, Simon Johnson (Corporate Broking)

Tel: + 44 (0) 20 7220 0500

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Jessica Hodgson / Laura Thornton

synairgen@consilium-comms.com

Tel: +44 (0) 20 3709 5701

About Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Leveraging scientific and clinical trial facilities at the University of Southampton and Southampton General Hospital, the Company uses in vitro and ex vivo models to progress opportunities into clinical development. The BioBank of human samples is used in these models to increase confidence in the likelihood of successful drug development. Core to Synairgen's business strategy is the realisation of value via licensing transactions - validated in June 2014 by the SNG001 agreement formed with AstraZeneca. In August 2015 the Company entered into a collaboration with Pharmaxis to develop an oral LOXL2 inhibitor to reduce fibrosis in patients with idiopathic pulmonary fibrosis (IPF). Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLLLFEEVRISFID

(END) Dow Jones Newswires

March 27, 2017 02:01 ET (06:01 GMT)

Synairgen (LSE:SNG)
Historical Stock Chart
From Apr 2024 to May 2024